Oncobiologics, Inc. (NASDAQ:OTLK) Receives $9.60 Average PT from Analysts
Shares of Oncobiologics, Inc. (NASDAQ:OTLK – Get Free Report) have received an average recommendation of “Moderate Buy” from the five research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year target price […]
Shares of Oncobiologics, Inc. (NASDAQ:OTLK – Get Free Report) have received an average recommendation of “Moderate Buy” from the five research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year target price […]
